OMGA241220C7500
- 0.05
- 0.000.00%
Omega Therapeutics Newsroom
Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines and Montai Therapeutics Under Its Strategic Partnership With Pfizer
Raymond James Downgrades Omega Therapeutics(OMGA.US) to Hold Rating
Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform
Piper Sandler Maintains Omega Therapeutics(OMGA.US) With Buy Rating, Cuts Target Price to $4
Piper Sandler Remains a Buy on Omega Therapeutics (OMGA)
Express News | Omega Therapeutics Inc : Piper Sandler Cuts Target Price to $4 From $9
Omega Therapeutics Names Kaan Certel as CEO
Omega Therapeutics Restructures Leadership and Strategic Focus
Express News | Omega Therapeutics Q3 2024 GAAP EPS $(0.30) Misses $(0.28) Estimate, Sales $2.612M Beat $1.240M Estimate
Omega Therapeutics Completes Phase 1 MYCHELANGELO I Clinical Trial And A Strategic Prioritization Of Its Pipeline
Omega Therapeutics: Prioritizing Select Preclinical Programs in Three Areas >OMGA
Omega Therapeutics: Jennifer Nelson Named as Chief Scientific Officer >OMGA
Omega Therapeutics 3Q Rev $2.61M >OMGA
Omega Therapeutics 3Q Loss/Shr 30c >OMGA
Omega Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Omega Therapeutics Inc - Collaboration With Novo Nordisk for Development of an Epigenomic Controller for Obesity Continues to Advance
Express News | Omega Therapeutics Inc - Otx-2002 Shows Favorable Safety Profile in Phase 1 Trial
Express News | Omega Therapeutics Inc - Exploring Partnerships for Phase 2 Development of Otx-2002
Express News | Omega Therapeutics Inc - Appoints Kaan Certel as CEO
Express News | Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results